Pesquisas alternativas:
after last » after blast (Expandir a Pesquisa), after laser (Expandir a Pesquisa), after lasik (Expandir a Pesquisa)
last phase » blast phase (Expandir a Pesquisa), yeast phase (Expandir a Pesquisa), gait phase (Expandir a Pesquisa)
phase rate » phase route (Expandir a Pesquisa), phase rule (Expandir a Pesquisa), phase role (Expandir a Pesquisa)
after last » after blast (Expandir a Pesquisa), after laser (Expandir a Pesquisa), after lasik (Expandir a Pesquisa)
last phase » blast phase (Expandir a Pesquisa), yeast phase (Expandir a Pesquisa), gait phase (Expandir a Pesquisa)
phase rate » phase route (Expandir a Pesquisa), phase rule (Expandir a Pesquisa), phase role (Expandir a Pesquisa)
21
Por Ding, Yue, Zeng, Jian‐Cheng, Yin, Fei, Zhang, Chun‐lin, Zhang, Yan, Li, Shi‐xun, Liu, Xun, Zhang, Chao, Xue, Qing‐yun, Lin, Hua, Pei, Fu‐xing
Publicado no Orthop Surg (2017)
“...OBJECTIVE: It has been reported that acute‐phase reactions (APR) after infusion of 5 mg zoledronic...”Publicado no Orthop Surg (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
22
Por Solomkin, Joseph S., Ramesh, Mayakonda Krishnamurthy, Cesnauskas, Gintaras, Novikovs, Nikolajs, Stefanova, Penka, Sutcliffe, Joyce A., Walpole, Susannah M., Horn, Patrick T.
Publicado em 2014
“... at the test-of-cure (TOC) visit 10 to 14 days after the last dose of study drug therapy. Overall, 53 patients...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
23
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV...
Por Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Publicado no PLoS Med (2018)
“... participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time...”Publicado no PLoS Med (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
24
Por File, Thomas M, Goldberg, Lisa, Das, Anita, Sweeney, Carolyn, Saviski, John, Gelone, Steven P, Seltzer, Elyse, Paukner, Susanne, Wicha, Wolfgang W, Talbot, George H, Gasink, Leanne B
Publicado no Clin Infect Dis (2019)
“... after the last dose of the study drug in the modified ITT (mITT) and clinically evaluable (CE...”Publicado no Clin Infect Dis (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
25
Por Heineman, Thomas C, Bernstein, David, Wald, Anna, Van Wagoner, Nicholas, Leone, Peter, Mayer, Kenneth, Lucksinger, Gregg, Win, Sandra, Koltun, William, Desai, Nisha, Oliphant, Thomas, Natenshon, Andrew, McNeil, Lisa K, Flechtner, Jessica B, Hetherington, Seth
Publicado no Open Forum Infect Dis (2017)
“... rate, recurrence frequency and recurrence duration through 6 months after the last dose. Local...”Publicado no Open Forum Infect Dis (2017)
Obter o texto integral
Obter o texto integral
Artigo
26
Por Suenaga, Mitsukuni, Nishina, Tomohiro, Mizunuma, Nobuyuki, Yasui, Hisateru, Ura, Takashi, Denda, Tadamichi, Ikeda, Junichi, Esaki, Taito, Nishisaki, Hogara, Takano, Yoshinao, Sugiyama, Yasuyuki, Muro, Kei
Publicado no BMC Cancer (2015)
“... was 1.1%, and the early death ≤30 days after the last study treatment was 1.1%. The incidence of grade 3...”Publicado no BMC Cancer (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
27
Por Ciurea, Stefan O., Schafer, Jolie R., Bassett, Roland, Denman, Cecele J., Cao, Kai, Willis, Dana, Rondon, Gabriela, Chen, Julianne, Soebbing, Doris, Kaur, Indreshpal, Gulbis, Alison, Ahmed, Sairah, Rezvani, Katayoun, Shpall, Elizabeth J., Lee, Dean A., Champlin, Richard E.
Publicado no Blood (2017)
“...Relapse has emerged as the most important cause of treatment failure after allogeneic hematopoietic...”Publicado no Blood (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
28
Por Colombo, Nicoletta, Zaccarelli, Eleonora, Baldoni, Alessandra, Frezzini, Simona, Scambia, Giovanni, Palluzzi, Eleonora, Tognon, Germana, Lissoni, Andrea A., Rubino, Daniela, Ferrero, Annamaria, Farina, Gabriella, Negri, Emanuele, Pesenti Gritti, Angela, Galli, Francesca, Biagioli, Elena, Rulli, Eliana, Poli, Davide, Gerardi, Chiara, Torri, Valter, Fossati, Roldano, D‘Incalci, Maurizio
Publicado no Br J Cancer (2019)
“... microenvironment and this could be synergistic with bevacizumab. The efficacy and safety of trabectedin...”Publicado no Br J Cancer (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
29
Por Navarria, P., Ascolese, A., Cozzi, L., Tomatis, S., Picozzi, P., Pecchioli, G., Attuati, L., Clerici, E., Maggi, G., Scorsetti, M.
Publicado no Neuro Oncol (2016)
“... to evaluate incidence of symptomatic radionecrosis, local control (LC) rate and patients overall survival...”Publicado no Neuro Oncol (2016)
Obter o texto integral
Obter o texto integral
Artigo
30
Por Oldach, David, Clark, Kay, Schranz, Jennifer, Das, Anita, Craft, J Carl, Scott, Drusilla, Jamieson, Brian D., Fernandes, Prabhavathi
Publicado em 2013
“... of clinical success at the test-of-cure visit 4 to 11 days after the last dose of study drug were comparable...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
31
Por Tashkin, Donald P, Doherty, Dennis E, Kerwin, Edward, Matiz-Bueno, Carlos E, Knorr, Barbara, Shekar, Tulin, Banerjee, Sibabrata, Staudinger, Heribert
Publicado em 2012
“... for subjects whose morning FEV(1) data were collected >2 days after the last dose of study treatment...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
32
Por Mehra, Ranee, Seiwert, Tanguy Y., Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P., Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Geva, Ravit, Chung, Hyun Cheol, Lin, Chia-Chi, Aurora-Garg, Deepti, Ray, Archana, Pathiraja, Kumudu, Cheng, Jonathan, Chow, Laura Q. M., Haddad, Robert
Publicado no Br J Cancer (2018)
“...) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab...”Publicado no Br J Cancer (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
33
Por Schmitt-Hoffmann, Anne, Roos, Brigitte, Maares, Jürgen, Heep, Markus, Spickerman, Jochen, Weidekamm, Erhard, Brown, Tom, Roehrle, Michael
Publicado em 2006
“... is in line with the long elimination half-life of BAL4815 determined after the last administration (mean...”Publicado em 2006
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
34
Por Qingsong Ye, Hua Wang, Xia Xia, Chenliang Zhou, Zhiming Liu, Zun-en Xia, Zhan Zhang, Yang Zhao, Jun Yehenala, Si Wang, Gangqiao Zhou, Ke Hu, Bin Wu, Chu-Tse Wu, Songling Wang, Yan He
Publicado em 2020-06-01
“...Abstract Objectives To assess the safety and therapeutic effects of allogeneic human dental pulp...”Publicado em 2020-06-01
Obter o texto integral
Artigo
35
Por Chouffai, Zoubir
Publicado em 2010
“... rates, favorable safety and toxicity profiles, and prolonged survival when used for the treatment...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
36
Por Jae-Yong Nam, Tae Yong Lee, Kwijoo Kim, Sehwan Chun, Min Sung Kim, Jin-Hong Shin, Jung-Joon Sung, Byoung Joon Kim, Byung-Jo Kim, Ki-Wook Oh, Kyung Suk Kim, Seung Hyun Kim
Publicado em 2022-05-01
Assuntos:
“...Phase III...”Publicado em 2022-05-01
Obter o texto integral
Artigo
37
Por Ben-Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., Van den Abbeele, A. D., Solomon, S. M., Fletcher, J. A., Demetri, G. D., George, S.
Publicado no Ann Oncol (2016)
“...BACKGROUND: This investigator-initiated trial provided the justification for the phase III GRID...”Publicado no Ann Oncol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
38
Por Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Publicado no J Immunother Cancer (2018)
“... Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti...”Publicado no J Immunother Cancer (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
39
Por Iguchi, Taro, Tamada, Satoshi, Kato, Minoru, Yasuda, Sayaka, Yamasaki, Takeshi, Nakatani, Tatsuya
Publicado no BMC Cancer (2019)
“... period is 6 months after the last patient registration. The main result will be reported in March 2019...”Publicado no BMC Cancer (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
40
Por Gloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, William Kilembe, Elwyn Chomba, François Roman, Patricia Bourguignon, Marguerite Koutsoukos, Alix Collard, Gerald Voss, Dagna Laufer, Gwynn Stevens, Peter Hayes, Lorna Clark, Emmanuel Cormier, Len Dally, Burc Barin, Jim Ackland, Kristen Syvertsen, Devika Zachariah, Kamaal Anas, Eddy Sayeed, Angela Lombardo, Jill Gilmour, Josephine Cox, Patricia Fast, Frances Priddy
Publicado em 2015-01-01
“...-specific antibody responses were induced. Immune responses persisted at least a year after the last...”Publicado em 2015-01-01
Obter o texto integral
Artigo